Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 13/20 | 0.59 |
| ▸ | MMP8 | P22894 | 12/20 | 0.59 |
| ▸ | MMP2 | P08253 | 10/20 | 0.59 |
| ▸ | MMP1 | P03956 | 6/20 | 0.51 |
| ▸ | FCER2 | P06734 | 2/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556742 | 0.84 | MMP9 (0.58) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL5557641 | 0.79 | MMP9 (0.45) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL3796377 | 0.77 | MMP8 (0.79) | MMP9MMP8MMP2MMP1MMP7 | |
| SCHEMBL6013881 | 0.77 | MMP8 (0.79) | MMP9MMP8MMP2MMP1MMP7 | |
| SCHEMBL7367696 | 0.76 | MMP1 (0.69) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL5558431 | 0.75 | MMP9 (0.80) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL5552720 | 0.75 | MMP9 (0.80) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL7374482 | 0.74 | MMP1 (0.72) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL5556805 | 0.74 | MMP9 (0.79) | MMP9MMP8MMP2MMP1FCER2 | |
| SCHEMBL7370265 | 0.74 | MMP1 (0.57) | MMP9MMP8MMP2MMP1FCER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP9 182/4885MMP8 24/4885MMP2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.